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Background: Ascites may affect the progression of ovarian cancer (OC). In particular, soluble factors present in OC
ascites can create a protective environment for tumor cells that promote de novo resistance to drug- and death
receptor-induced apoptosis. However, the underlying molecular mechanisms responsible for ascites-induced drug
resistance are not well characterized.
Methods: Using human OC cell lines and tissues microarrays of human OC biopsies, we assessed the mechanism
by which OC ascites increase Mcl-1 expression using Western blots, chemical inhibitors of ERK and small-inhibitory
RNA treatments.
Results: In the present study, we found that both Mcl-1 mRNA and protein levels were upregulated within 2 h
upon treatment of OC cells with ascites obtained from women with advanced OC. In contrast, the expression of
other Bcl-2 family antiapoptotic members such as Bcl-2 and Bcl-XL was not affected by ascites. An increase of Mcl-1
expression was consistently observed across different ascites from women with advanced serous OC. The
knockdown of Mcl-1 significantly blocked ascites-induced Mcl-1 upregulation and ascites-mediated inhibition of
TRAIL-induced apoptosis. Ascites induced a rapid phosphorylation of ERK1/2 and Elk-1 transcription factor.
Furthermore, we found that ERK1/2 inhibition or Elk-1 knockdown was sufficient to block ascites-induced Mcl-1
expression. In high grade serous OC, we found a positive correlation between phosphorylated ERK1/2 and Mcl-1
expression.
Conclusions: These results indicate that ascites-induced ERK1/2/Elk-1 signaling is critical for Mcl-1 expression and
for the ascites-mediated attenuation of TRAIL-induced apoptosis. The ERK1/2/Elk-1/Mcl-1 pathway represents a
novel mechanism by which ascites induce de novo TRAIL resistance in OC cells.
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Ovarian cancer (OC) is the fifth cause of cancer-related
death in women, the second most common gynecological
cancer, and the leading cause of death from gynecological
malignancies [1-3]. High grade serous OC is the most
common subtype of OC and over 70% of these patients
present with late stage diseases and dissemination of
tumor implants throughout the peritoneal cavity [4,5].* Correspondence: Alain.Piche@USherbrooke.ca
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distribution, and reproduction in any mediumDespite initial aggressive treatment, the five-year survival
of patients with late stage disease remains at < 30%, a
figure that has not changed for the past 30 years [2]. This
is related, at least in part, to the persistence of minimal re-
sidual disease after chemotherapy, which contributes to
shorter progression-free survival [6,7]. The tumor envir-
onment is being increasingly recognized as an important
contributor of tumor progression [8-10] as it may facilitate
the survival [11-14], differentiation and proliferation of
tumor cells [15,16]. Furthermore, ascites create a protect-
ive environment for ovarian tumor cells that inhibit drug-
induced apoptosis (de novo resistance) [13,17]. Ascites are
heterogenous fluids that display marked differences inioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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potentially activate an array of signaling pathways [18-24].
The demonstration that ascites with prosurvival properties
are associated with a shorter progression-free survival in
patient with OC underscores the critical role of ascites in
OC progression [6]. The molecular changes in tumor cells
induced by ascites that result in resistance have not been
well characterized. It is important to define the contribu-
tion of each pathway both to fully understand cell survival
signaling and to validate individual pathways as thera-
peutic targets.
Activation of the Raf/MEK/ERK pathway has been
often associated with the promotion of cell proliferation
but also represents, in addition to the PI3K/Akt path-
way, an important survival signaling pathway in many
tumor cells [25]. The Raf/MEK/ERK pathway promotes
survival through the inhibition of the apoptotic cascade
by controlling the expression or the activity of Bcl-2
family members [26,27]. There is evidence that the ERK
pathway activation increases the expression of prosurvi-
val Bcl-2 proteins, notably Mcl-1, by promoting de novo
gene expression [26,28-30]. The relative expression of
Mcl-1 in tumor cells can be regulated at the transcrip-
tional level or through post translational modifications
by ERK [31]. In addition to the ERK signaling, the PI3K/
Akt pathway has been found to be critical for Mcl-1 ex-
pression [32-34]. The importance of Mcl-1 in mediating
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) resistance has been well documented in differ-
ent cell types [35]. Overexpression of Mcl-1 can attenu-
ate apoptosis induced by TRAIL [36]. Conversely,
downregulation of Mcl-1 by siRNA enhances TRAIL-
mediated cell death [37].
TRAIL belongs to the TNF family of cytokines and has
emerged as a promising anticancer agent, because of its
ability to selectively induce apoptosis in a broad host of
tumor cells [35,38]. TRAIL binding to its receptors
(TRAIL-R1 and TRAIL-R2) initiates the extrinsic path-
way, resulting in recruitment of the adapter protein Fas-
associated death domain (FADD) and procaspase-8 in
the death inducing signaling complex (DISC). In some
cells (type I cells), the apoptotic signal from active
caspase-8 is sufficient to activate downstream effector
caspases and induce apoptosis [39]. However, in other
cell types, such as OC cells, the apoptotic signal must be
further amplified by engaging the intrinsic (mitochon-
drial) pathway [39]. In this context, caspase-8 cleaves
Bid to generate an active tBid, which in turn activates
proapoptotic Bax or Bak proteins, and induces mito-
chondrial outer membrane permeabilization (MOMP).
The mitochondria then releases proapoptotic factors
that promote effector caspase activation. Overexpression
of antiapoptotic Bcl-2 family members, including Bcl-2,
Bcl-XL and Mcl-1 is associated with TRAIL resistance intype II cells, because of their ability to prevent tBid-
induced MOMP [40].
In this study, we demonstrate that transcriptional
upregulation of Mcl-1 by OC ascites is mediated by an
ERK-dependent activation of the transcription factor
Elk-1. Moreover, we demonstrate that upregulation of
Mcl-1 has a significant role in ascites-mediated attenu-
ation of TRAIL-induced apoptosis.
Results
OC ascites upregulate Mcl-1 expression
Previous studies have shown that OC ascites obtained
from women with advanced disease attenuate TRAIL-
induced apoptosis [13,17], and ascites with prosurvival
activity negatively affect progression-free survival [6].
One of the mechanisms by which ascites attenuate
TRAIL-induced apoptosis in OC cells is through engage-
ment of αvβ5 integrin and subsequent activation of Akt
survival signaling pathway which results in the upregula-
tion of caspase-8 inhibitor c-FLIPs [13,17]. However,
given the relative abundance of survival factors in asci-
tes, other signaling pathways likely contribute to pro-
mote TRAIL resistance. Microarray data analysis of OC
cells (CaOV3) exposed to ascites revealed that Mcl-1
was one of the genes differentially upregulated (data not
shown). Because several studies in various cancer types
have demonstrated that overexpression of the antiapop-
totic protein Mcl-1 may promote TRAIL resistance [35],
we examined the contribution of Mcl-1 to ascites-
induced TRAIL resistance in the TRAIL-sensitive OC
cell line CaOV3 and OVCAR3. OVCAR3 is an ovarian
carcinoma cell line isolated from malignant ascites that
is resistant to clinically relevant concentrations of cis-
platin but remains sensitive to TRAIL-induced apop-
tosis. CaOV3 is also an ovarian carcinoma cell line
isolated from a patient with advanced disease. Both cell
lines have been extensively used by our group and the
TRAIL signaling cascade has been well characterized
[41-43]. In addition, we have previously shown that
TRAIL-induced apoptosis is inhibited by OC ascites in
these cell lines [13,17]. We first examined Mcl-1 protein
and mRNA levels in CaOV3 and OVCAR3 cell lines fol-
lowing treatment with ascites. As shown in Figure 1A,
CaOV3 cells demonstrated a marked increase of Mcl-1
protein within 2 h of exposure to OVC508 ascites, which
remained elevated for up to 12 h. Expression of antia-
poptotic proteins Bcl-2 and Bcl-XL remained however
unchanged following treatment with OVC508 ascites.
To ensure that ascites effect on Mcl-1 was not limited to
a single ascites, additional ascites were tested and all
consistently upregulated Mcl-1 at 2 h, albeit to different
degrees, without affecting Bcl-2 or Bcl-XL (Figure 1B).
Mcl-1 protein was also upregulated by ascites in the
OVCAR3 cell line (Figure 1C and Additional file 1:
Figure 1 OC ascites stimulate Mcl-1 protein and mRNA levels. (A) Time course of Mcl-1 protein expression in CaOV3 cells following addition
of 10% OVC508 ascites to the cell culture media. Cells were incubated with complete media for 24 h before the addition of ascites. Immunoblots
were probed with anti-Mcl-1, anti-Bcl-2, anti-Bcl-XL and anti-tubulin (as a loading control). (B) Immunoblot analysis of Mcl-1, Bcl-2, Bcl-XL and
tubulin expression in CaOV3 cells incubated with different OC ascites (10%). Lysates were obtained 2 h following the addition of ascites. (C) Time
course of Mcl-1 expression in OVCAR3 cells following addition of 10% OVC508 ascites. (D) Real-time PCR analysis of Mcl-1 transcript levels in the
presence or absence of OVC508 ascites (10%) and actinomycin D. Results were standardized using primers of the housekeeping gene RPLPO.
Results are expressed as fold change relative to basal levels observed in cells incubated in the absence of ascites. (E) Immunoblot analysis of
basal levels of Mcl-1 protein in CaOV3 and OVCAR3 cells. (F) Quantitative real-time PCR of Mcl-1 mRNA expression levels. Expression data were
normalized to internal RPLPO RNA expression. Data represents the mean of two experiments ± SEM. ** indicates P < 0.001.
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changes were the result of increased transcription or
altered protein stability, we examined Mcl-1 mRNA
levels in CaOV3 and OVCAR3 cells at 2 h following ex-
posure to ascites. Mcl-1 mRNA levels, as determined by
quantitative real time PCR, were upregulated by at least
two fold in both CaOV3 and OVCAR3 cells, which
could be inhibited by pretreatment with actinomycin D
(Figure 1D and Additional file 1: Figure S1B) indicating
that this was due to transcriptional increase, rather than
a change in the mRNA stability. This was further sup-
ported by the observation that ascites did not alter Mcl-
1 protein stability (Additional file 1: Figure S1C). Indeed,
when levels of Mcl-1 were depleted in OVCAR3 cells
incubated for 4 h in the presence of cycloheximide
(10 μg/ml) to block de novo protein biosynthesis, theturnover of Mcl-1 was not affected by the addition of
ascites. Of note, the magnitude of Mcl-1 upregulation
was not as strong in OVCAR3 cells when compared
to CaOV3 cells but OVCAR3 cells expressed higher
basal levels of Mcl-1 protein (Figure 1E) and mRNA
(Figure 1F). All together, these data demonstrate that
OC ascites upregulate Mcl-1 expression in OC cells.
Mcl-1 contributes to ascites-induced attenuation of TRAIL-
mediated apoptosis
Given its antiapoptotic activity, Mcl-1 could contribute
to ascites-induced attenuation of TRAIL-induced apop-
tosis. Thus, we investigated whether Mcl-1 inhibition
can alter the prosurvival activity of OC ascites. First,
CaOV3 cells were incubated with ascites in the presence
or absence of TRAIL (50 ng/ml) for 24 h. Long term cell
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viving colonies after two weeks. As shown in Figure 2A,
the addition of OVC508 or OVC509 ascites to CaOV3
cells significantly (P < 0.0001) enhanced the fraction of
survival cells. When apoptosis was determined by meas-
uring the sub-G1 DNA content for CaOV3 and
OVCAR3 cells incubated with ascites, we observed a
38% to 48% decreased of TRAIL-induced apoptosis
(P < 0.001) confirming that ascites attenuate TRAIL-Figure 2 Mcl-1 inhibition abrogates the prosurvival activity of ascites
term assays where cells were exposed to TRAIL (50 ng/ml) for 24 h in the a
were counted and expressed as percentage of colonies obtained in the ab
percentage of hypodiploid cells assessed by flow cytometry analysis during
24 h in the presence or absence of OVC508 ascites. (C) CaOV3 and OVCAR3
and apoptosis was assessed by flow cytometry 24 h later. (D) CaOV3 and (E
presence or absence of OVC508 ascites. Mcl-1 knockdown was confirmed b
a loading control. Apoptosis was assessed 24 h following siRNA transfectio
means ± SEM derived from three independent experiments. * indicates P <mediated cytotoxicity (Figure 2B). These data confirmed
that pretreatment with ascites attenuates TRAIL-
induced apoptosis in OC cells.
When CaOV3 and OVCAR3 cells were compared dir-
ectly, the level of TRAIL-induced apoptosis was higher
in CaOV3 cells (Figure 2C), consistent with the observation
that CaOV3 cells expressed lower basal level of
Mcl-1 (Figure 1E and 1F). To further assess the role
of Mcl-1 in TRAIL resistance, CaOV3 cells were. (A) The effect of ascites on CaOV3 cell survival was assessed by long
bsence (control) or presence of ascites (10%). After 14 days colonies
sence of TRAIL. (B) The percentage of apoptosis was measured as
exposure to TRAIL (50 ng/ml for CaOV3; 100 ng/ml for OVCAR3) for
cells were treated with a similar concentration of TRAIL (50 ng/ml)
) OVCAR3 cells were transfected with Mcl-1 or control siRNA in the
y immunoblot analysis 24 h after transfection and ERK1/2 was used as
n in the presence or absence of TRAIL (50 ng/ml). Data shown are
0.01, ** P < 0.001, *** P < 0.0001.
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pression of Mcl-1 was assessed by immunoblot at
24 h and 48 h post transfection. Mcl-1 protein was effi-
ciently downregulated by Mcl-1 siRNA in CaOV3 cells
(Additional file 1: Figure S2A). Importantly, transfection
of CaOV3 and OVCAR3 cells with Mcl-1 siRNA com-
pletely abrogated ascites-induced Mcl-1 upregulation in
both CaOV3 (Figure 2D) and OVCAR3 cells (Figure 2E).
Of note, the expression of antiapoptotic protein Bcl-2 and
Bcl-XL remained unaffected by Mcl-1 siRNA (Additional
file 1: Figure S2B). Mcl-1 depletion significantly blocked
the prosurvival activity of ascites in CaOV3 and OVCAR3
cells. As shown in Figure 2D, TRAIL (50 ng/ml) induced
apoptosis in CaOV3 cells whereas the presence of ascites,
as expected, significantly inhibited TRAIL-induced apop-
tosis (P < 0.001). In CaOV3 cells transfected with Mcl-1
siRNA, the protective effect of ascites was almost com-
pletely abrogated. The transfection of Mcl-1 siRNA in
OVCAR3 cells also significantly (P < 0.01) inhibited the
protective effect of ascites albeit to a lesser extend
(Figure 2D). This could be related to the observation that
the Mcl-1 siRNA did not completely block Mcl-1 expres-
sion in OVCAR3 cells.
OC ascites upregulate Mcl-1 through ERK1/2 signaling
Activation of both ERK1/2 and Akt pathways has
been linked to the transcriptional regulation of Mcl-1
[26,28-30,32,34]. Previous studies demonstrating Akt ac-
tivation by ascites [13,17] prompted us to investigate
whether Akt and ERK1/2 were involved in ascites-
mediated upregulation of Mcl-1 expression. First, we
examined the phosphorylation of Akt and ERK1/2 over-
time and found that both Akt and ERK1/2 were acti-
vated by ascites (Figure 3A and Additional file 1:
Figure S3). siRNA-mediated inhibition of Akt in both
CaOV3 and OVCAR3 cells however did not altered
ascites-mediated up-regulation of Mcl-1 expression
(Figure 3B). The chemical inhibitor of Akt LY294002 pro-
duced similar results (data not shown) suggesting that
ascites-mediated Mcl-1 up-regulation is not dependent of
Akt activation. In contrast, when ERK1/2 activation was
inhibited by the specific MEK1/2 inhibitor U0126 [44],
ascites-mediated upregulation of Mcl-1 protein was sub-
stantially blocked in both CaOV3 and OVCAR3 cells
(Figure 3C). Consistent with these results, U0126 signifi-
cantly blocked the transcriptional upregulation of Mcl-1
by ascites in CaOV3 and OVCAR3 cells (Figure 3D). In
contrast, the inhibition of Akt by LY294002 had no impact
on ascites-mediated transcriptional upregulation of Mcl-1
in OC cells (Figure 3D). Because Mcl-1 contributes to
ascites-mediated protection from TRAIL-induced apop-
tosis, we examined whether ERK1/2 has a similar role. As
expected, ERK1/2 inhibition by U0126 significantly
blocked ascites-mediated protection from TRAIL-inducedapoptosis (Figure 3E). These data demonstrate that ERK1/
2 activation upregulates Mcl-1 expression and contributes
to ascites-mediated attenuation of TRAIL-induced
apoptosis.
Ascites activates Elk-1 transcription factor via ERK1/2
pathway
Previous studies have shown that ERK1/2 can directly
phosphorylate and activate many transcription factors
including Elk-1 in breast cancer cells [28]. ERK1/2 acti-
vation promotes Elk-1 phosphorylation at Ser383 and its
activation. We therefore determine whether ascites treat-
ment of OC cells resulted in activation of Elk-1. As
shown in Figure 4A, the treatment of CaOV3 and
OVCAR3 cells with OVC415 ascites resulted in Elk-1
phosphorylation (Ser383) within 30 min and phosphoryl-
ation declined thereafter. This was similar to the kinetic
of ERK1/2 that was observed in CaOV3 and OVCAR3
cells (Figure 3A). To ensure that ascites-induced Elk-1
phosphorylation was not limited to a single ascites,
CaOV3 and OVCAR3 cells were treated with OVC508
and Elk-1 activation was assessed. As shown in
Figure 4B, treatment with OVC508 also resulted in Elk-1
activation. Pretreatment with U0126 prevented both
ascites-induced ERK1/2 and Elk-1 phosphorylation in
CaOV3 and OVCAR3 cells (Figure 4B). These data dem-
onstrate that ascites-induced Elk-1 activation is ERK1/2-
dependent in OC cells.
Ascites-dependent Elk-1 activation is responsible for
Mcl-1 regulation
To determine whether ascites-induced activation of
Elk-1 transcription factor is responsible for Mcl-1 upre-
gulation, OVCAR3 cells were transfected with Elk-1 or
control siRNA and the expression of Elk-1 and Mcl-1
were determined 24 h later by immunoblot. As shown in
Figure 5A, the knockdown of Elk-1 inhibited upregula-
tion of Mcl-1 by ascites indicating a critical role of Elk-1
in Mcl-1 upregulation. Similar to what we observed in
OVCAR3 cells, CaOV3 cells transfected with Elk-1
siRNA displayed reduced Mcl-1 expression at 24 h and
48 h following treatment with OVC415 and OVC439 as-
cites (Figure 5B).
Ascites-mediated ERK/Ekl-1 signaling is independent of
FAK activation
It has been previously shown that OC ascites induce a
α6β1 integrin-dependent activation of ERK1/2 pathway
[24] and a αvβ5 integrin-mediated activation of Akt
pathway [13]. The engagement of integrins to the extra-
cellular matrix (ECM) components triggers a signaling
cascade that leads to the activation of focal adhesion
kinase (FAK), one of the earliest events that immediately
follows integrin-ECM component engagement. In this
Figure 3 ERK1/2 signaling regulates the Mcl-1 expression. (A) Immunoblot analysis of Akt, phospho-Akt, ERK1/2 and phospho-ERK1/2 in
CaOV3 and OVCAR3 cells following the addition of 10% OVC508 ascites. (B) Expression levels of Akt, phospho-Akt and Mcl-1 in vehicle, Akt or
control siRNA-transfected CaOV3 and OVCAR3 cells 24 h post-transfection in the presence or absence of OVC508 ascites. (C) Immunoblot analysis
of ERK1/2, phospho-ERK1/2 and Mcl-1 in OVC508 ascites- and U0126-treated OVCAR3 and CaOV3 cells 24 h post treatement. (D) Real-time PCR
analysis of Mcl-1 transcript levels in CaOV3 and OVCAR3 cells. Cells were treated with either ascites (OVC508), MEK1/2 inhibitor U0126 or Akt
inhibitor LY294002 and RNA was extracted 4 h later. Results were standardized using primers of the housekeeping gene RPLPO. Results are
expressed as fold change relative to basal levels observed in cells incubated in the absence of ascites. (E) Apoptosis was assessed 24 h following
incubation with U0126 in the presence or absence of TRAIL 50 ng/ml for CaOV3 cells and 100 ng/ml for OVCAR3 cells. Data shown are
means ± SEM derived from three independent experiments. * indicates P < 0.001, ** P < 0.0001.
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Figure 4 Elk-1 is activated by ascites and its activation is controlled by ERK1/2. (A) Cells were treated with OVC415 ascites (10%) for up to
240 min and the expression and phosphorylation of Elk-1 was assessed by immunoblot. Activation of Elk-1 was detected with an anti-phospho-
Elk-1 antibody specific for Ser383. Tubulin was used as a control for loading. (B) Cells were treated with U0126 for 1 h before the addition of
OVC415 ascites (10%). Lysates were obtained 1 h after the addition of ascites and immunoblot analysis was performed with anti-phospho-ERK1/2
and anti-phospho-Elk-1 antibodies. Representative data from three independent experiments.
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rapid FAK activation [13]. Thus, we assessed whether
FAK was involved in ascites-mediated activation ofFigure 5 Elk-1 activation is essential for the control of Mcl-1 expressio
siRNA luciferase (siRNA Luc) or Elk-1 specific siRNA (siRNA Elk-1) and 24 h la
with FBS. Lysates were obtained 1 h after the stimulation with ascites and
Mcl-1 antibodies. Tubulin was used as a loading control. (B) CaOV3 cells we
and 24 or 48 h later cells were stimulated with either OVC415 (left panel) o
immunoblotted with anti-Elk-1, anti-Mcl-1, anti-phospho-Elk-1 and anti-tubuERK1/2/Elk-1 signaling. To this end, CaOV3 and
OVCAR3 cells were transfected with FAK or control
siRNA and cells were treated with ascites. Figure 6n. (A) OVCAR3 cells were transfected with vehicule (control), control
ter cells were treated with OVC415 ascites for 1 h or left in medium
immunoblots were probed with anti-phospho-Elk-1, anti-Elk-1 and anti-
re transfected with vehicule, control siRNA Luc or Elk-1 specific siRNA
r OVC439 ascites (right panel). Lysates were obtained and
lin. Representative data from three independent experiments.
Figure 6 Ascites-induced ERK1/2 activation is independent from the activation of FAK. (A) Immunoblot analysis of expression and
activation of FAK in both CaOV3 and OVCAR3 cells in the presence of ascites (OVC415). (B) Cells were transfected with vehicle (control), control
luciferase siRNA (siRNA Luc) or FAK siRNA (siRNA FAK) and 24 h later cells were stimulated with OVC415 ascites for 1 h. Lysates were then
obtained and analyzed by immunoblot for total and phospho-FAK (Tyr397), phospho-Akt (Ser473), phospho-ERK1/2, phospho-Elk-1 and Mcl-1.
Representative data from three independent experiments.
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ascites-induced Akt activation as we have previously
reported [13]. In contrast, ERK1/2 activation was not
affected by FAK knockdown. Consistent with this obser-
vation, Elk-1 activation and Mcl-1 expression remained
unaffected by FAK knockdown. These data suggest
that integrin/FAK signaling is not critical for Mcl-1
upregulation.
Activated ERK1/2 correlates with Mcl-1 expression in high
grade serous OC (HGSOC)
To determine whether our in vitro findings were clinic-
ally relevant in human ovarian tumors, we assessed if
the ERK1/2-dependent regulation of Mcl-1 expression in
CaOV3 and OVCAR3 cell lines correlated in HGSOC,
the most common subtype of OC. We initially per-
formed a pilot study on 20 HGSOC samples to deter-
mine the optimal conditions for antibody staining
against Mcl-1, phospho-ERK1/2 and phospho-Elk-1.
Despite several attempts, we were unable to obtained
consistent staining for phospho-Elk-1. Based upon this
pilot study, we examined the relationship between phos-
pho-ERK1/2 and Mcl-1 expression in a tissue microarray
(TMA) of HGSOC provided by the Pan-canadian plat-
form for the development of biomarker-driven subtype
specific management of ovarian carcinoma (COEUR
study). The TMA consisted of 120 HGSOC samples and
each tumor was represented by two separate spots on
the TMA. The immunostaining was scored using a 0–3
scoring system (H-score). Representative images fromthe sampled tumors demonstrate that regions within
individual section expressing Mcl-1 also have positive
phospho-ERK1/2 staining (Figure 7A). The data was
analyzed by plotting the scores as an XY scatter and
performing a Spearman correlation test (Figure 7B). We
found a statistically significant positive correlation
between the phosphorylation of ERK1/2 and Mcl-1 expres-
sion (rs = 0.46, P = 0.015). The tumors were separated into
two groups based on the median Mcl-1 H-score of 62.5.
Samples with a score < 62.5 were classified as low Mcl-1
and those with a score > 62.5 were classified as high Mcl-1
(Figure 7C). The median phospho-ERK1/2 for the low
Mcl-1 group was 12 and the median for the high Mcl-1
group was 46, a difference that was statistically significant
using a Mann–Whitney test (P = 0.008). These data sup-
port the regulation of Mcl-1 expression by the ERK1/2
pathway in HGSOC.
Discussion
The development of resistance to chemotherapy remains
a major problem with OC. Indeed, the poor prognosis is
usually attributed to the occurrence of resistance.
Defects in the apoptotic cascade have been commonly
associated with resistance in OC cells. Although a num-
ber of mechanisms have been proposed for OC cells,
most studies were performed in unicellular models and
did not take into account the interactions that exist be-
tween the host and tumor cells. Unlike most other solid
cancers where the stroma surrounding tumor cells con-
stitutes the tumor environment, ascites that develop
Figure 7 Activated ERK1/2 correlates with Mcl-1 expression in HGSOC samples. A TMA containing samples from 120 HGSOC was stained
by immunohistochemistry with antibodies specific for phospho-ERK1/2 and Mcl-1. Tumors were scored using the H-score method.
(A) Representative images of immunoperoxidase-stained tissue for phospho-ERK1/2 and Mcl-1 demonstrating either negative staining (0), low
intensity (1) or high intensity staining (3). (B) Correlation chart for Mcl-1 and ERK between their H-scores as determined by
immunohistochemistry. (C) H-score for phospho-ERK1/2 separated into two groups based on the median Mcl-1 H-score of 62.5.
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tumor environment. Indeed, soluble factors in ascites
create a proinflammatory environment that promotes de
novo resistance [13,17]. Available evidence suggests that
soluble factors in the tumor environment engage cellsurface receptors to activate survival pathways [13]. This
study extends our previous findings that ascites-induced
activation of the Akt pathway attenuates TRAIL-induced
apoptosis [13,17] by showing that ERK1/2/Elk-1 signal-
ing is responsible for the transcriptional increase of Mcl-1,
Goncharenko-Khaider et al. Molecular Cancer 2012, 11:84 Page 10 of 13
http://www.molecular-cancer.com/content/11/1/84which in turn contributes to ascites-mediated inhibition
of TRAIL-induced apoptosis in OC cells. Our results show
that ascites induce a rapid activation of Akt and ERK1/2
but only that ERK1/2 activation is associated with Mcl-1
upregulation in tumor cells. Moreover, our results demon-
strate that Mcl-1 upregulation is one of the mechanisms
by which ascites protect OC cells from against TRAIL-
induced apoptosis.
Although we have previously reported that one malig-
nant ascites (COV2) induced the phosphorylation of Akt
but not ERK [17], further works, as shown here and by
other groups [24], have demonstrated that ERK activa-
tion by various OC ascites is a common findings. Similar
observations have been made for the activation of the
Akt pathway by ascites. Many ascites have the ability to
activate this pathway [6,13,17] but it appears that some
OC ascites are unabled to increase Akt phosphorylation
in OC cell lines [6,13]. This is believed to be related to
the heterogeneity of OC ascites.
TRAIL cytotoxicity in OC cells relies on the activation
of both the extrinsic and the intrinsic apoptotic path-
ways [39]. These two pathways are interconnected, and
in OC cells, the proapoptotic Bcl-2 family member Bid
is a critical regulator of TRAIL resistance that connects
both pathways by promoting mitochondrial activation
[41]. Antiapoptotic Bcl-2 family proteins, such as Bcl-2,
Bcl-XL and Mcl-1, have a critical role in regulating the
balance between survival and death signals at the mito-
chondrial level. Although Bcl-XL may promote the sur-
vival of OC cells [42,45], the importance of Mcl-1 in OC
survival has not been well established. Higher expression
of Mcl-1 in OC compared to adenomas or normal ovar-
ies has been reported [46-48], and was, in some studies,
associated with poor prognosis [47]. Our study shows
that Mcl-1, but not Bcl-2 nor Bcl-XL, is upregulated by
OC ascites. Mcl-1 is a downstream target of activated
ERK signaling and is important for survival of OC cells
in response to TRAIL since siRNA inhibition of Mcl-1
significantly attenuates ascites-mediated resistance to
TRAIL.
Ascites-induced signaling events trigger activation of
both the Akt and the ERK1/2 pathways. We have previ-
ously shown that ascites-mediated Akt activation attenu-
ates TRAIL-induced apoptosis in CaOV3 cells [17].
Ascites activate Akt, which in turn up-regulate the ex-
pression of cFLIPs, a caspase-8 inhibitor. The treatment
of CaOV3 cells with PI3K/Akt inhibitors partially blocks
ascites-mediated survival [17]. Activation of the PI3K/
Akt pathway thus represents one way by which ascites
confer resistance to TRAIL-induced apoptosis. The
present study suggests that ERK1/2 pathway mediates
the transcriptional upregulation of Mcl-1. Unlike inhib-
ition of ERK1/2, blocking Akt pathway did not alter
ascites-induced upregulation of Mcl-1. This is evidencedby the lack of effect of Akt downregulation by siRNA
and Akt inhibition by LY294002 on Mcl-1 expression. In
contrast, U0126-mediated inhibition of ERK1/2 readily
decreased Mcl-1 at the transcriptional level, and pro-
moted TRAIL-induced apoptosis in OC cells. These
results indicate that ERK1/2, but not Akt pathway, plays
a determining role in ascites-induced Mcl-1 expression.
The ERK1/2 pathway has been previously reported
to regulate Mcl-1 transcription in other cell types
[26,28-30]. In addition, the activation of ERK1/2 in OC
has been shown to enhance tumor progression [49,50].
Activation of the ERK1/2 pathway has also been
involved in tumor cell survival by coupling survival
stimulus to transcription factors controlling gene expres-
sion. For example, higher levels of phospho-ERK1/2 in
OVCAR3 cells were associated with increased resistance
to cisplatin [51]. In addition, the resistance to paclitaxel
can be partially obliterated when ERK1/2 activity is
inhibited [52]. The correlation between ERK1/2 activa-
tion and Mcl-1 expression in tumor samples from
patients with HGSOC suggest that the ERK1/2/Mcl-1
pathway likely exerts a protective anti-apoptotic effect to
tumor cells and is biologically relevant.
Our data indicate that the Elk-1 transcription factor is
an important regulator of ascites-induced Mcl-1 expres-
sion. OC ascites induced a rapid (within 30 min) phos-
phorylation of Elk-1 in tumor cells. Although other
transcription factors such as Stat3 and NF-κB have been
reported to regulate Mcl-1 expression [31], it appears
that Elk-1 is critical in OC cells as evidenced by the fact
that siRNA inhibition of Elk-1 almost completely abol-
ished ascites-induced Mcl-1 upregulation. In accordance
with our results, Elk-1-dependent regulation of Mcl-1
expression has been described with other types of cancer
[27,28]. Additional studies have shown that Elk-1 is dir-
ectly phosphorylated by ERK1/2 [28] and therefore sup-
port our findings that ascites induce phosphorylation of
not only ERK1/2 but also Elk-1.
We have previously shown that soluble factors present
in OC ascites engage αvβ5 integrin to induce a FAK-
dependent Akt activation that contributes to protect
cells from TRAIL-induced apoptosis [13]. Here, we dem-
onstrate that ERK1/2 activation, which contributes to
decrease TRAIL-induced apoptosis, is independent from
ascites-mediated FAK activation as shown by the fact
that the knockdown of FAK does not affect ERK1/2 and
Elk-1 phosphorylation. Although growth factor receptors
such as EGFR and PDGFR can often activate the ERK
pathway [25], and ligands of these receptors are present
in OC ascites [53], we do not believe that the ascites-
mediated upregulation of Mcl-1 is dependent on these
receptors because we previously shown that the inhib-
ition of EGFR and PDGFR does not alter the prosurvival
activity of ascites [13].
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signaling pathways to inhibit TRAIL-induced apoptosis
and each pathway may contribute to a different level to
ascites-mediated protection from TRAIL depending, at
least in part, on the cell context. Although the signifi-
cance of these in vitro observations in regard to the
clinic has yet to be determined, we propose that ascites,
by activating different survival pathways in tumor cells,
contribute to the persistence of tumor cells during treat-
ment and the occurrence of resistance. This has implica-
tion from a therapeutic standpoint. Targeting the tumor
environment could be an important strategy to sensitize
OC cells to chemotherapy.
Materials and methods
Cell culture and reagents
The human OC cell lines CaOV3 and OVCAR3 were
obtained from the American Type Culture Collection
(Manassas, VA) and maintained in a humidified 5% CO2
incubator at 37°C. Cells were passaged twice weekly.
OVCAR3 cells were maintained in RPMI-1640 (Wisent,
St-Bruno, QC, Canada) supplemented with 20% FBS, insu-
lin (10 mg/L), glutamine (2 mM) and antibiotics. CaOV3
cells were cultured in DMEM/F12 (Wisent) supplemented
with 10% FBS, 2 mM glutamine and antibiotics. TRAIL
was purchased from PeproTech (Rocky Hill, NJ). Acellular
ascites fractions OVC415, OVC508, OVC509, OVC551
were obtained at the time of initial cytoreductive surgery
from women with advanced serous ovarian carcinomas.
Samples were supplied by the Banque d’échantillons biolo-
giques (seins/ovaires) et de données de Sherbrooke as part
of the Banque de tissus et de données du Réseau de
Recherche en Cancer des Fonds de Recherche en Santé
du Québec (FRSQ) affiliated to the Canadian Tumor
Repository Network (CTRNet). HRP-conjugated anti-
mouse and -rabbit antibodies, Akt, Bcl-XL, Elk-1, phos-
pho-ERK1/2 (Thr202/Tyr204), Mcl-1, FAK, phospho-FAK
and phospho-Elk-1 (Ser383) antibodies were purchased
from Cell Signaling. Antibodies for phospho-Akt (Ser473)
were from Life Technologies (Burlington, ON). Bcl-2 anti-
body was purchased from Dako (Burlington, ON). ERK
antibody was from Santa Cruz Biotech (Santa Cruz, CA).
PI3K inhibitor LY294002 and MEK inhibitor U0126 were
purchased from EMD (Billerica, MA). Tubulin antibody,
actinomycin D and propidium iodide were purchased
from Sigma-Aldrich (Oakville, ON). Actinomycin D was
dissolved in dimethyl sulfoxide at a concentration of
10 mM and stored at −20°C.
Quantitative real time PCR
Total RNA was extracted from CaOV3 and OVCAR3 cells
using TRIzol reagent (Life Technologies) according to the
manufacturer’s protocol and subjected to reverse transcrip-
tion (RT) with oligodT from Promega (Madison, WI) andMMULV reverse transcriptase enzyme. RNA concentrations
were quantified by measurement of absorbance at 260 nm.
The integrity of the cDNA was assessed with the Taqman
gene expression assays (Life Technologies), done on RPLPO
housekeeping gene. Each sample was normalized to the
housekeeping gene levels. Mcl-1 primers were from Life
Technologies (gene expression assay hs03043899, cat
# 4331182). Cycle conditions for all PCRs were as follow: an
initial incubation of 2 min at 95°C followed by 35 cycles at
94°C 30 s, 55°C 30 s, 72°C 60 s. The amplification occurred
for 2 min at 72°C. PCR products quantification was per-
formed as previously described in collaboration with Dr
C. Asselin (université de Sherbrooke) [41].
Apoptosis assays
Analysis of apoptosis was performed by quantification of
the sub-G1 peak by flow cytometry as previously
described [41]. Propidium iodide staining for DNA frag-
mentation was done by fixing cells and staining them
with propidium iodide for DNA analysis content as pre-
viously described [41]. A total of 10,000 events were
analyzed by flow cytometry and the percentage of hypo-
diploid cells was measured using a BD FACScalibur flow
cytometer (BD Biosciences, ON, Canada).
Western blot analysis
Cells were harvested and washed with ice-cold PBS. Whole
cell extracts were prepared in lysing buffer (glycerol 10%,
Triton X-100 1%, TRIS 10 mM pH 7.4, NaCl 100 mM,
EGTA 1 mM, EDTA 1 mM, SDS 0.1%) containing protease
inhibitors (0.1 mM AEBSF, 5 μg/ml pepstatin, 0.5 μg/ml leu-
peptin and 2 μg/ml aprotinin) and phosphatase inhibitors
(Na4P2O7 20 mM, NaF 1 mM, Na3VO4 2 mM). Proteins
were separated by 12% SDS-PAGE gels. Proteins were trans-
ferred to PVDF membranes (Roche, Laval, Québec, Canada)
by electroblotting, and immunoblot analysis was performed
as previously described [17]. All primary antibodies were
incubated overnight at 4°C in 5% fat-free milk. Proteins were
visualized by enhanced chemiluminescence (GE Healthcare,
Baie d’Urfé, Québec, Canada).
siRNA transfections
The Fluorescein-labeled Luciferase GL2 duplex or a non-
target (scrambled) siRNAs used as a control were from
Dharmacon Research (Lafayette, CO). Cells (6 × 104) were
seeded in 6-well plates and allowed to adhere for 24 h.
Cells (50% confluent) were transfected with a mixture
containing Lipofectamine 2000™ (Life Technologies), opti-
MEM (Life Technologies) and siRNA (10 μM). The siR-
NAs/Lipofectamine complex was then added to the media
of 6-well plates containing cells. Cells were incubated for
4–6 h at 37°C in a CO2 incubator and medium containing
FBS was then added. The Mcl-1 and FAK siRNAs were
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ing and Elk-1 siRNA from Santa Cruz.
Immunohistochemistry staining
TMAs were acquired from the Pan-canadian platform for
the development of biomarker-driven subtype specific
management of ovarian carcinoma (COEUR study).
Sections were deparaffinized in citrate buffer containing
0.05% Tween at 97°C for 20 min, washed with PBS and
incubated with 3% peroxide. After treatment, slides were
submerged in a citrate buffer (0.01 M citric acid, pH 6.0)
for 15 min, and incubated with a protein blocking serum-
free reagent (Dako Canada). The TMAs were stained by
an immunoperoxidase method using an automated tissue
immunostainer (Dako Canada) with DABchromogen. The
TMAs counter stained with hematoxilin and were visua-
lized by light microscopy at 20× magnification and scored
by two blinded independent observers using the H-score
method with an inter-rating > 90%. An intensity score of
0–3 was multiplied by the percentage of tumor cells
stained to obtain the H-score. P values were calculated by
the Mann–Whitney test.
Statistical analysis
Statistical comparisons between two groups were per-
formed using the Mann–Whitney or Student’s t-test.
The correlation between phosphor-ERK1/2 and Mcl-1
expression in tissue section was determined by the
Spearman correlation test. Statistical significance was
indicated by P < 0.05.
Additional file
Additional file 1: Figure S1. - (A) Time course of Mcl-1 protein
expression in OVCAR3 cells following addition of 10% OVC509 and
OVC551 ascites to the cell culture media. Cells were incubated with
ascites for 2 h and 4 h and proteins were extracted. Immunoblots were
probed with anti-Mcl-1 and anti-tubulin antibodies (as a loading control).
(B) Real-time PCR analysis of Mcl-1 transcript levels from CaOV3 cells
incubated in the presence or absence of OVC415 and OVC509 ascites
(10%) and actinomycin D. Results were standardized using primers of the
housekeeping gene RPLPO. Results are expressed as fold change relative
to basal levels observed in cells incubated in the absence of ascites. (C)
OVCAR3 cells were treated with protein synthesis inhibitor cycloheximide
2 h before addition of OVC509 ascites. Lysates were obtained after 3 h
and immunoblot analysis of Mcl-1 were performed. Figure S2. – (A)
CaOV3 cells were transfected with vehicle, Mcl-1 or control siRNA. Mcl-1
knockdown was assessed by immunoblot analysis 24 h and 48 h after
transfection. ERK1/2 was used as a loading control. (B) CaOV3 were
transfected as described and Bcl-2 and Bcl-XL expression were
determined 24 h after transfection of Mcl-1 siRNA to ensure that Mcl-1
knockdown does not altered Bcl-2 and Bcl-XL expression. Figure S3. – (A)
CaOV3 cells were incubated with various ascites (10%) for 2 h. Akt
phosphorylation and expression were then determined by immunoblot. (B)
CaOV3 cells were incubated with OVC 439 ascites and Akt phosphorylation
and expression were assessed at 2 h and 4 h after addition of ascites.
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